In this issue:
- Managing ICI-induced inflammatory arthritis: rheumatologists versus oncologists
- Long-term clinical outcomes for early RA treated-to-target
- Upadacitinib in early vs. established axial SpA
- Allopurinol use and ACS risk in gout
- Nonarticular pain at early RA diagnosis
- Sustained DMARD-free remission in RA subgroups
- Anxiety and depression in RA patients
- Baricitinib for early polymyalgia rheumatica
- Responsiveness/sensitivity of PROMs to disease activity changes in early and established RA
- Infliximab or adalimumab in refractory severe mucocutaneous Behçet’s syndrome
Please login below to download this issue (PDF)